Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | AHR | P35869 | 13/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16345161 | 0.79 | MCL1 (0.54) | MCL1AHRMAOAMAOBSIRT2 | |
| SCHEMBL28730094 | 0.75 | MCL1 (0.50) | MCL1AHRCA1CA2SIRT2 | |
| SCHEMBL16345420 | 0.75 | MCL1 (0.54) | MCL1AHRCA1CA2SIRT2 | |
| SCHEMBL18325887 | 0.75 | MCL1 (0.50) | MCL1AHRMAOBSIRT2 | |
| SCHEMBL16632699 | 0.75 | MCL1 (0.50) | MCL1AHRF2RL3 | |
| SCHEMBL16632612 | 0.74 | CA12 (0.35) | MCL1MAOBCA1CA2F2RL3 | |
| SCHEMBL6779123 | 0.72 | MCL1 (0.51) | MCL1AHRMAOACA1CA2 | |
| SCHEMBL16345431 | 0.68 | MCL1 (0.43) | MCL1 | |
| SCHEMBL31326155 | 0.64 | AHR (0.42) | AHRF2RL3 | |
| SCHEMBL23597817 | 0.64 | AHR (0.46) | MCL1AHRMAOAMAOBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | MCL1 2386/4885AHR 3451/4885MAOA 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.